Fusion Antibodies reports progress with DR5 project.

Fusion Antibodies said on Monday that its grant-funded DR5 project with Queen’s University Belfast had made further progress, with the antibody successfully humanised using the company’s proprietary CDRx platform and several more complex structural variants showing positive results in tumour cell death assays.

Fusion Antibodies
15 June 2026 16:10:38

Source: Sharecast

The AIM-traded antibody discovery and engineering specialist said the gene encoding the lead humanised antibody had also been inserted into a stable cell line suitable for large-scale manufacture.

It said new microfluidic technology at the Future Medicines Institute had reduced the cell line development timeline by about 50% to around four months.

Fusion said UK Research & Innovation had agreed to extend the project’s completion date to 31 December from 31 October, allowing further pre-clinical evaluation in cancer models.

Chief executive Adrian Kinkaid said the InnovateUK grant support had allowed the project to progress “smoothly and successfully”, while chief scientific officer Richard Buick said the latest variants had shown “robust activity in induced cancer cell death assays”.

At 1501 BST, shares in Fusion Antibodies were up 0.17% at 12.02p.

Reporting by Josh White for Sharecast.com.

See latest RNS on Investegate

N/A

ISIN: N/A

Exchange: N/A

Sell:

N/A

Buy:

N/A

Change:

Date:

Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

View our accounts

Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.